KCA
FULC icon

KVP Capital Advisors’s Fulcrum Therapeutics FULC Stock Holding History

KVP Capital Advisors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50,000
Closed -$566K – 34
2025
Q4 		$566K Buy
+50,000
New +$509K 0.55% 25

Other funds holding FULC

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $935M AUM 298.58% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

KVP Capital Advisors's FULC Position: Q1 2026 in Review

KVP Capital Advisors sold out of Fulcrum Therapeutics (FULC) in Q1 2026, closing a stake of 50,000 shares — an estimated $566K sold.

KVP Capital Advisors first reported a position in FULC in Q4 2025 and held it in 1 quarter. The position peaked at $566K in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • KVP Capital Advisors reported no remaining Fulcrum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • KVP Capital Advisors sold 50,000 Fulcrum Therapeutics shares in Q1 2026, an estimated $566K.
  • KVP Capital Advisors first reported a position in Fulcrum Therapeutics in Q4 2025 and held it in 1 quarter.
  • KVP Capital Advisors's Fulcrum Therapeutics position peaked at $566K in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on KVP Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.